biostudies-literatureHamilton KWNIAID NIH HHSofae388https://www.ebi.ac.uk/biostudies/studies/S-EPMC11297503biostudies-literatureUnknown11(8)<h4>Background</h4>During the COVID-19 pandemic, SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis (SMA-PrEP) offered patients who were immunocompromised another option for protection. However, SMA-PrEP posed administrative, operational, and ethical challenges for health care facilities, resulting in few patients receiving them. Although the first SMA-PrEP medication, tixagevimab and cilgavimab, had its authorization revoked due to compromised in vitro efficacy, new SMA-PrEP medications are currently completing clinical trials. This article provides an operational framework for administrative organization, patient identification and prioritization, equitable medication allocation, medication ordering and administration, and patient tracking.<h4>Methods</h4>A retrospective cohortOpen forum infectious diseasesImplementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center.PMC11297503UM1 AI144288Fernandez Lynch HPayne ASDutcher LTakach PTebas PDoucette AGCraig ECivitello TBlumberg EAAhya VNDegnan KOHolzman LJacobs DAGeara AHua EHamilton KWKoenig HPratz KKannel EZGabriel PWerner DJunker PGarfall ACapozzi DfalseImplementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center.<h4>Background</h4>During the COVID-19 pandemic, SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis (SMA-PrEP) offered patients who were immunocompromised another option for protection. However, SMA-PrEP posed administrative, operational, and ethical challenges for health care facilities, resulting in few patients receiving them. Although the first SMA-PrEP medication, tixagevimab and cilgavimab, had its authorization revoked due to compromised in vitro efficacy, new SMA-PrEP medications are currently completing clinical trials. This article provides an operational framework for administrative organization, patient identification and prioritization, equitable medication allocation, medication ordering and administration, and patient tracking.<h4>Methods</h4>A retrospective cohort2024-01-01T00:00:00Z2024 Aug2026-05-04T06:47:05.402Z2025-02-19T04:40:33.832ZS-EPMC112975033910052810.1093/ofid/ofae388